Paul E. Hanna, MD MSc (@paulhannamd) 's Twitter Profile
Paul E. Hanna, MD MSc

@paulhannamd

Director of Onconephrology @MCW_nephrology via @MGHkidneys @BWHkidney| @HarvardChanSPH Graduate | Chair @Onconephsociety | Ed fellow @KidneyNews | #OLIC_app

ID: 1450989965274501121

linkhttps://onconephrology.mgh.harvard.edu/home_page/about/ calendar_today21-10-2021 00:59:22

835 Tweet

835 Followers

730 Following

Sanjeev Sethi (@sethirenalpath) 's Twitter Profile Photo

Membranoproliferative GN (MPGN) 1. Original GBM stays INTACT 2. + New GBM made, entrapping immune/complement 3. Results in 2 GBM: original & new= double contour 4. Double contour results in ⬇️ leukocytes=⬇️ inflammation Seen in chronic disease:hepatitis, monoclonal Ig, C3G

Membranoproliferative GN (MPGN)

1. Original GBM stays INTACT 

2. + New GBM made, entrapping immune/complement

3. Results in 2 GBM: original & new= double contour 

4. Double contour results in ⬇️ leukocytes=⬇️ inflammation

Seen in chronic disease:hepatitis, monoclonal Ig, C3G
Sandra Herrmann MD, FASN (@herrmannmd) 's Twitter Profile Photo

Onconephrology Symposium this year at Mayo Clinic , join us and also consider submitting your research abstract. Great opportunity for networking and learning the latest updates in this field. American Society of Onconephrology Mayo Clinic Nephrology

NKF Nephrology Professionals (@nkf_nephpros) 's Twitter Profile Photo

NKF Chief Medical Officer Joseph Vassalotti, MD is kicking off “Late-Breaking Abstracts”. First up is Dr. Si Yuan Khor to cover re-defining carboplatin dosage using eGFR-creatinine-cystatin C compared to Cockcroft Gault and impact on platinum-associated adverse events.  #NKFClinicals

NKF Chief Medical Officer <a href="/Joe_Vassalotti/">Joseph Vassalotti, MD</a> is kicking off “Late-Breaking Abstracts”. First up is Dr. Si Yuan Khor to cover re-defining carboplatin dosage using eGFR-creatinine-cystatin C compared to Cockcroft Gault and impact on platinum-associated adverse events. 
#NKFClinicals
NKF Nephrology Professionals (@nkf_nephpros) 's Twitter Profile Photo

“Using eGFR-CR-CYS to dose carboplatin would lead to significant differences in administered doses of carboplatin in 26% of treated patients” shared Dr. Si Yuan Khor. #NKFClinicals

“Using eGFR-CR-CYS to dose carboplatin would lead to significant differences in administered doses of carboplatin in 26% of treated patients” shared Dr. Si Yuan Khor. #NKFClinicals
Kenar Jhaveri (@kdjhaveri) 's Twitter Profile Photo

New "X"orial alert 1/ What medications, if any, do you give to prevent cisplatin-associated acute kidney injury (CP-AKI )? A new paper in JAMA Oncology led by Shruti Gupta and David Leaf found that IV magnesium may reduce the risk of CP-AKI. Here’s a brief #tweetorial

Mohamed H. Hassanein | محمد هشام حسنين 🇪🇬 (@kidneymo) 's Twitter Profile Photo

🎉 Excited to share our mini-glomerular disease series on StatPearls.com! 🔹 4 PubMed-indexed, free, and continuously updated chapters 🔹 A multi-institutional collaboration 🔹 Fellows gain first-author experience 🔹 All content reviewed by field experts A great resource and

🎉 Excited to share our mini-glomerular disease series on <a href="/StatPearls1/">StatPearls.com</a>!
🔹 4 PubMed-indexed, free, and continuously updated chapters
🔹 A multi-institutional collaboration
🔹 Fellows gain first-author experience
🔹 All content reviewed by field experts
A great resource and